$664 Million is the total value of Sarissa Capital Management LP's 11 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 30.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AGN | Buy | ALLERGAN PLC | $127,083,000 | +74.0% | 868,000 | +58.8% | 19.13% | +18.2% |
| BIIB | Buy | BIOGEN INC | $124,018,000 | -10.8% | 524,658 | +13.6% | 18.67% | -39.4% |
| IRWD | Buy | IRONWOOD PHARMACEUTICALS INC. | $102,045,000 | +57.5% | 7,542,200 | +20.6% | 15.36% | +7.0% |
| MDCO | Buy | MEDICINES CO | $101,626,000 | +90.9% | 3,636,000 | +30.7% | 15.30% | +29.7% |
| INVA | Buy | INNOVIVA INC | $84,546,000 | -4.1% | 6,026,100 | +19.3% | 12.73% | -34.8% |
| PBYI | Buy | PUMA BIOTECHNOLOGY INC | $54,965,000 | +101.1% | 1,417,000 | +5.5% | 8.28% | +36.6% |
| ICPT | Buy | INTERCEPT PHARMACEUTICALS INC | $35,795,000 | +557.8% | 320,000 | +492.6% | 5.39% | +346.8% |
| MRSN | New | MERSANA THERAPEUTICS INC | $19,725,000 | – | 3,750,000 | +100.0% | 2.97% | – |
| JAZZ | New | JAZZ PHARMACEUTICALS INC | $14,295,000 | – | 100,000 | +100.0% | 2.15% | – |
| ABBV | ABBVIE INC | $80,000 | -13.0% | 1,000 | 0.0% | 0.01% | -40.0% | |
| MRTX | MIRATI THERAPEUTICS INC | $73,000 | +73.8% | 1,000 | 0.0% | 0.01% | +22.2% | |
| SHPG | Exit | SHIRE PLCsponsored adr | $0 | – | -1,000 | -100.0% | -0.04% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BIOGEN INC. | 32 | Q3 2023 | 37.1% |
| INNOVIVA INC. | 29 | Q3 2023 | 19.5% |
| IRONWOOD PHARMACEUTICALS INC. | 24 | Q3 2023 | 24.2% |
| ABBVIE INC. | 23 | Q2 2020 | 24.4% |
| MEDICINES CO. | 20 | Q4 2019 | 33.9% |
| MERSANA THERAPEUTICS INC. | 19 | Q3 2023 | 7.9% |
| ALKERMES PLC | 16 | Q3 2023 | 43.7% |
| INTERCEPT PHARMACEUTICALS INC. | 15 | Q2 2021 | 10.7% |
| BIOCRYST PHARMACEUTICALS INC | 14 | Q3 2023 | 7.4% |
| VIVUS INC | 14 | Q1 2017 | 8.8% |
View Sarissa Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Alkermes plc. | August 24, 2023 | 8,323,400 | 5.0% |
| Innoviva, Inc. | May 15, 2023 | 6,904,000 | 10.5% |
| IRONWOOD PHARMACEUTICALS INC | March 01, 2021 | 14,890,000 | 9.3% |
| Iterum Therapeutics plcSold out | February 12, 2021 | 0 | 0.0% |
| BIOCRYST PHARMACEUTICALS INC | January 25, 2021 | 8,844,000 | 5.0% |
| Mersana Therapeutics, Inc. | January 25, 2021 | 3,770,000 | 5.5% |
| MEDICINES CO /DESold out | January 07, 2020 | 0 | 0.0% |
| Regulus Therapeutics Inc. | January 03, 2020 | 7,935,322 | 29.4% |
| NOVELION THERAPEUTICS INC. | November 09, 2018 | 909,296 | 4.6% |
| APRICUS BIOSCIENCES, INC. | September 05, 2018 | 1,152,455 | 4.8% |
View Sarissa Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-03-19 |
| 13F-HR | 2024-02-14 |
| 4 | 2023-12-19 |
| SC 13D/A | 2023-12-05 |
| 13F-HR | 2023-11-14 |
| 4 | 2023-09-19 |
| SC 13D/A | 2023-09-05 |
| SC 13D/A | 2023-08-24 |
| 13F-HR | 2023-08-14 |
| DFAN14A | 2023-06-28 |
View Sarissa Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.